Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Hanwha Ocean Shares Rise on Plans to Expand U.S. Shipbuilding Capacity 
 Annual Meeting 2016 - EconoTimes)
WEST LAFAYETTE, Ind., April 11, 2016 -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the American Association for Cancer Research (AACR) Annual Meeting 2016 to be held in New Orleans, April 16-20, 2016.
The presentation materials will be available on Endocyte’s website following presentation at the conference.
Presentations are as follows:
| Abstract #: | 262 |
| Title: | Combination therapy of folate-targeted chemotherapeutics with anti-PD-1 antibody against folate receptor-positive tumors in immunocompetent murine models |
| When: | Sunday, April 17, 1 p.m. – 5 p.m. EDT |
| Session Title: | Combination Chemotherapy |
| Location: | Halls G-J, Poster Section 15 |
| Abstract #: | 3035 |
| Title: | Development and characterization of CCK2R-targeted SMDCs and identification of GIST as a potential therapeutic indication |
| When: | Tuesday, April 19, 8 a.m. – 12 p.m. EDT |
| Session Title: | Novel Targets and Pathways |
| Location: | Halls G-J, Poster Section 17 |
| Abstract #: | 3754 |
| Title: | Pre-clinical studies of a highly potent Folate receptor targeted DNA crosslinking agent |
| When: | Tuesday, April 19, 1 p.m. – 5p.m. EDT |
| Session Title: | Novel Antitumor DNA-Reactive Agents |
| Location: | Halls G-J, Poster Section 16 |
| Abstract #: | 4735 |
| Title: | Designing Novel Warheads for Targeted Therapies: SAR and Efficient Strategies for Synthesis of Analogs of Tubulysin |
| When: | Wednesday, April 20, 8 a.m. – 12 p.m. EDT |
| Session Title: | HDAC, Methyltransferase Inhibitors, and Novel Anticancer Agents |
| Location: | Halls G-J, Poster Section 17 |
About Endocyte
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. Endocyte uses its proprietary drug conjugation technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly active drugs at greater doses, delivered more frequently and over longer periods of time than would be possible with the untargeted drug alone. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. For additional information, please visit Endocyte’s website at www.endocyte.com.
Contacts: Stephanie Ascher, Stern Investor Relations, Inc., (212) 362-1200, [email protected]
